01:40 , Jan 27, 2018 |  BioCentury  |  Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier Brandicourt...
01:27 , Jan 13, 2018 |  BioCentury  |  Strategy

Remapping growth

As patisiran and fitusiran get closer to market, Alnylam Pharmaceuticals Inc. and Sanofi Genzyme concluded that the territorial complexity of their partnership for the products would limit their commercial value. Amendments announced on Jan. 7...
00:05 , May 20, 2017 |  BioCentury  |  Strategy

Henri: N of 1

Gaucher’s disease had swollen Brian Berman’s spleen to the size of a basketball and physicians at NIH told the three-year-old’s parents that it had to be removed. It was 1984, there was no effective treatment...
17:22 , May 15, 2017 |  BC Extra  |  Company News

Orphan drug giant Termeer passes away

Henri Termeer, the former chairman, president and CEO of Genzyme Corp. and one of the handful of individuals who personified the biotech industry in its early decades, passed away May 12 at age 71. Termeer joined...
07:00 , Mar 28, 2016 |  BioCentury  |  Strategy

Canbridge can-can

Canbridge Life Sciences Ltd.'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its strategy,...
07:00 , Jun 8, 2015 |  BioCentury  |  Product Development

Perennial pioneer

Genzyme Corp. aims to remain a leader in Orphan diseases by adopting clinical innovations from oncology and continuing to engage patients from early research all the way to the market to speed development, approval and...
02:24 , Nov 22, 2014 |  BC Extra  |  Company News

Genzyme's Cerdelga gets CHMP nod for Gaucher's

EMA's CHMP recommended marketing authorization of Cerdelga eliglustat tartrate from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat Type I Gaucher's disease. Cerdelga is an oral ceramide analog that inhibits glucosylceramide synthase (GCS)....
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Cerdelga eliglustat tartrate regulatory update

FDA approved Cerdelga eliglustat from Sanofi’s Genzyme Corp. unit to treat Type I Gaucher’s disease. Genzyme plans to launch the oral ceramide analog that inhibits glucosylceramide synthase (GCS) in the U.S. within a...
07:00 , Sep 1, 2014 |  BioCentury  |  Strategy

Back to School: Paying the piper

Pharma has lost its pricing power in many countries, as evidenced by reimbursement authorities' willingness to delay or outright deny access to drugs whose costs are deemed unacceptable. Now, the availability of a costly drug...
01:47 , Aug 20, 2014 |  BC Extra  |  Company News

FDA approves Genzyme's Cerdelga

FDA approved Cerdelga eliglustat from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat Type I Gaucher's disease. The product is also under review in Europe for the indication. Genzyme said it plans to...